NCT06056830ClinicalTrials.gov
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study
باختصار
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
المرحلة 3مطلوب 383 مشاركاً34 موقعاً3 دول
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT06056830فتح هذا السجل في ClinicalTrials.govتمت المزامنة الأسبوع الماضي
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2023-09-28; recorded start 2023-12-21
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
- Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Clarity Pharmaceuticals Ltd)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Allocation not stated in the record
- Blinding0/20
Open-label
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 31 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 383 participants (target), run at 34 sites, across 3 countries.
How this score is built
- Enrolment25/40
383 participants (target)
- Site count18/25
31 sites
- Country count7/15
3 countries
- Planned duration8/10
Planned over about 33 months
- Sponsor scale2/10
Clarity Pharmaceuticals Ltd has led 5 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
الحالات
- Prostate Cancer
- Prostatic Neoplasms
الأهلية
| الجنس | ذكر |
|---|---|
| الأعمار | 18 Years – لا حد أقصى |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 3 |
| التخصيص | غير منطبق |
| نموذج التدخّل | SINGLE_GROUP |
| الغرض الأساسي | DIAGNOSTIC |
| التعمية | NONE (0) |
| التجنيد | مطلوب 383 مشاركاً |
الجهة الراعية والمتعاونون
- Clarity Pharmaceuticals Ltd الجهة الراعية
الأذرع والتدخلات
- 64Cu-SAR-bisPSMAEXPERIMENTAL
200MBq 64Cu-SAR-bisPSMA.
التدخلات
- دواء 64Cu-SAR-bisPSMA
All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
مقاييس النتائج
مقياس النتيجة الأولي
Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases
Independent primary endpoints for Day 1 and Day 2 PET: Co-primary endpoint of sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer within the pelvic lymph nodes compared to the Standard of Truth.
الإطار الزمني Up to 16 weeks
مقياس النتيجة الثانوي
Safety and tolerability of 64Cu-SAR-bisPSMA
Incidence and severity of treatment-emergent AEs and SAEs following administration of 64Cu-SAR-bisPSMA
الإطار الزمني Up to 16 weeks
مقياس النتيجة الثانوي
Consistency of 64Cu-SAR-bisPSMA PET/CT interpretations for the three central readers
Inter-reader reliability of agreement estimated with a multiple-reader kappa statistic
الإطار الزمني Up to 16 weeks
مقياس النتيجة الثانوي
PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs
PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth
الإطار الزمني Up to 16 weeks
مقياس النتيجة الثانوي
Ability of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer
Sensitivity of 64Cu-SAR-bisPSMA PET to detect PC within the prostate gland compared to the Standard of Truth
الإطار الزمني Up to 16 weeks
مقياس النتيجة الثانوي
Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases without subregion matching
Sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth, without the requirement of subregion (Left or Right) matching between 64Cu-SAR-bisPSMA PET and Standard of Truth
الإطار الزمني Up to 16 weeks
التواريخ
| تاريخ البدء | 21 ديسمبر 2023 (فعلي) |
|---|---|
| الإتمام الأولي | 1 سبتمبر 2026 (تقديري) |
| الإتمام | 1 سبتمبر 2026 (تقديري) |
| أول نشر | 28 سبتمبر 2023 (فعلي) |
| آخر تحديث | 11 سبتمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | سبتمبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
34 موقعاً قيد التجنيد
Australia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Fiona Stanley Hospital | Murdoch | Western Australia | قيد التجنيد |
| RAMSAY HEALTH CARE AUSTRALIA PTY LIMITED (ABN 36 003 184 889) trading as Hollywood Private Hospital | Nedlands | Western Australia | قيد التجنيد |
| St. Vincent's Sydney | Sydney | New South Wales | قيد التجنيد |
| Princess Alexandra Hospital | Woolloongabba | Queensland | قيد التجنيد |
Puerto Rico
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Pan American Center for Oncology Trials, LLC - Ciudadela | San Juan | قيد التجنيد |
United States
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Albany Medical College, Department of Urology | Albany | New York | قيد التجنيد |
| Urology Austin, PLLC - Research Department | Austin | Texas | قيد التجنيد |
| University of Alabama Birmingham Hospital | Birmingham | Alabama | قيد التجنيد |
| University of Texas Southwestern Medical Center | Dallas | Texas | قيد التجنيد |
| Urology Clinics of North Texas | Dallas | Texas | قيد التجنيد |
| Duke University Medical Center | Durham | North Carolina | قيد التجنيد |
| NorthShore University Health System, Glenbrook Hospital | Glenview | Illinois | قيد التجنيد |
| BAMF Health | Grand Rapids | Michigan | قيد التجنيد |
| Corewell Health | Grand Rapids | Michigan | قيد التجنيد |
| Indiana University School of Medicine | Indianapolis | Indiana | قيد التجنيد |
| Mayo Clinic- Jacksonville | Jacksonville | Florida | قيد التجنيد |
| Arkansas Urology Research Center, LLC | Little Rock | Arkansas | قيد التجنيد |
| Greater Los Angeles VA Medical Center | Los Angeles | California | قيد التجنيد |
| Urology Group of Southern California | Los Angeles | California | قيد التجنيد |
| University of Wisconsin | Madison | Wisconsin | قيد التجنيد |
| Biogenix Molecular, LLC | Miami | Florida | قيد التجنيد |
| Intermountain Health | Murray | Utah | قيد التجنيد |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | قيد التجنيد |
| Urology Associates of Nashville | Nashville | Tennessee | قيد التجنيد |
| Mount Sinai Doctors Urology Faculty Practice | New York | New York | قيد التجنيد |
| XCancer Omaha LLC | Omaha | Nebraska | قيد التجنيد |
| UC Irvine Health | Orange | California | قيد التجنيد |
| Mayo Clinic- Phoenix | Phoenix | Arizona | قيد التجنيد |
| Mayo Clinic- Rochester | Rochester | Minnesota | قيد التجنيد |
| The Urology Place | San Antonio | Texas | قيد التجنيد |
| Oregon Urology | Springfield | Oregon | قيد التجنيد |
| Stanford University Medical Center | Stanford | California | قيد التجنيد |
| Urologic Specialists | Tulsa | Oklahoma | قيد التجنيد |
| Wichita Urology Group | Wichita | Kansas | قيد التجنيد |
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 11 سبتمبر 2026
أُضيف موقع
3 sites added (34 total)
3134